Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482575 | 0.82 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNQ1KCNE1EPHX2 | |
| SCHEMBL25378382 | 0.82 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNQ1KCNE1EPHX2 | |
| SCHEMBL25375889 | 0.82 | EPHX2 (0.44) | EPHX2TRPV1 | |
| SCHEMBL25378193 | 0.80 | ABCG2 (0.47) | EPHX2PIK3CATRPV1PDE10ATP53 | |
| SCHEMBL25376142 | 0.79 | EPHX2 (0.45) | EPHX2TRPV1 | |
| SCHEMBL25341064 | 0.79 | TRPV1 (0.50) | EPHX2TRPV1 | |
| SCHEMBL25341133 | 0.78 | MKNK1 (0.51) | EPHX2TRPV1 | |
| SCHEMBL25974136 | 0.78 | EPHX2 (0.48) | EPHX2TRPV1GRM4 | |
| SCHEMBL25974137 | 0.78 | TRPV1 (0.49) | EPHX2TRPV1 | |
| SCHEMBL25974055 | 0.78 | EPHX2 (0.46) | EPHX2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |